Aurobindo Pharma reported INR29.08B in Cost of Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Cipla CIPLA:IN INR 20.04B 1.56B
Dr.Reddys Laboratories DRRD:IN INR 20.01B 1.54B
Hindustan Unilever HUVR:IN INR 81.08B 890M
Sun Pharmaceuticals SUNP:IN INR 28.04B 956M
UPL UPLL:IN INR 64.54B 6.73B